AVertto

Our vision is to preserve Improve the quality of life by reducing silent stroke impact. We will develop, manufacture, and introduce the first easy-to-use device for alerting stroke for high-risk populations. The first market is hospital use during sedation, with the end-stage market being home telemonitoring. The company has a clear patentable product, a large growing market, and an expert and experienced team. StrokeAlert's intellectual property is an alerting system via continuous monitoring of hemodynamic parameters (patent submitted). StrokeAlert's impact will be reducing morbidity and mortality from stroke. We shall compare patients' neurological outcomes with and without StrokeAlert. Problem: Stroke is the leading cause of disability and the leading cause of death for people over 60. It can be treated if detected on time. Stroke is only detected clinically. Stroke during sedation and sleep are significant causes of undetected stroke. A stroke occurs in up to 10% of surgeries (perioperative stroke), and 1 of 7 strokes occurs at sleep (wake-up stroke). The essence is that the inability to detect clinical changes in sedated/ sleeping people prevents proper and timely treatment. Solution: StrokeAlert will detect unilateral carotid hemodynamic changes reflecting stroke risk to provide timely alerts enabling early intervention. StrokeAlert develops a product: A medical device aimed at alerting the risk of stroke in sedated or sleeping patients. During the first phase, the device is for hospital usage in the operating theaters and intensive care units with a $2B market. In the second phase, StrokeAlert will develop a home-use device monitoring sleep in people with a higher risk of stroke with a €15B market. StrokeAlert seeks $2.5M for 2years: The first year ($1.25M) will be dedicated to reaching pre-production series and initial clinical studies. The second year ($1.25M) will focus on algorithm optimization, and transfer manufacturing.